Abstracts

A RANDOMIZED TRIAL OF SWITCHING TREATMENT-EXPERIENCED ADULTS FROM PI/r TO DTG

Dolutegravir (DTG) has shown good efficacy and tolerability among treatment-experienced adults with HIV. Most HIV-infected adults in Kenya with prior non-nucleoside reverse transcriptase inhibitor (NNRTI) failure are on ritonavir-boosted protease inhibitor (PI/r)-based second line regimens. We evaluated the efficacy and safety of switching virally suppressed adults from a second-line PI/r-containing regimen to a DTG-containing regimen,…

NUCLEOSIDES AND DARUNAVIR/DOLUTEGRAVIR IN AFRICA (NADIA) TRIAL: OUTCOMES AT 96 WEEKS

At 48 weeks, the NADIA trial found non-inferiority of dolutegravir versus darunavir and non-inferiority of maintaining tenofovir versus switching to zidovudine in second-line therapy. WHO guidelines continue to recommend a switch to zidovudine. We report new follow-up data to end of trial at week 96. Patients failing NNRTl/tenofovir/lamivudine first-line with confirmed VL ?1000 copies/ml were…

LENACAPAVIR AS PART OF A COMBINATION REGIMEN IN TREATMENT NAÏVE PWH: WEEK 54 RESULTS

Lenacapavir (LEN), a potent first-in-class inhibitor of capsid function, is in development for treatment and prevention of HIV-1. CALIBRATE is an ongoing, open-label, phase 2 study evaluating subcutaneous (SC) and oral LEN, in combination with other antiretrovirals, in treatment-naïve people with HIV-1 (PWH). At Week 28 (W28), LEN + emtricitabine/tenofovir alafenamide (F/TAF) led to high…

PHASE I STUDY OF LONG-ACTING 3BNC117 AND 10-1074 IN VIREMIC ADULTS LIVING WITH HIV

Several anti-HIV-1 broadly neutralizing antibodies (bNAbs) targeting different envelope epitopes are being evaluated as long-acting alternatives or adjuvants to antiretrovirals (ART) for prevention and therapy, or as part of remission strategies. The combination of 3BNC117 and 10-1074 induced significant reductions in viremia and maintained viral suppression during ART interruption in individuals harboring antibody-sensitive viruses. Here,…

PREVALENCE OF SYPHILIS AND HIV/SYPHILIS COINFECTION IN 5 SUB-SAHARAN COUNTRIES

HIV and syphilis are common sexually transmitted infections globally and in sub-Saharan Africa (SSA); however, most prevalence data come from clinical cohorts. We examined the prevalence of syphilis in the general population and associated demographic and behavioral factors using Population-based HIV Impact Assessment (PHIA) surveys conducted by ministries of health of each country in collaboration…

CHANGES IN HIV AND STI TESTING AND DIAGNOSES DURING THE COVID-19 PANDEMIC

The COVID-19 pandemic led to significant disruptions in the provision of routine medical services. Myriad pandemic-related factors such as access to healthcare facilities, virtual care delivery, social distancing, changes in sexual behaviors, and periodic swab shortages may have affected detection rates for HIV and other sexually transmitted infections (STIs). Thus, we evaluated trends in testing…

CDC’S DIRECT-TO-CONSUMER DISTRIBUTION OF 100,000 HIV SELF-TESTS

To directly support the federal Ending the HIV Epidemic (EHE) initiative and accelerate the identification of undiagnosed infections in the US, CDC implemented a program aimed to mail 100,000 HIV self-tests to prioritized populations at-risk for HIV through paid advertising, social media, and partner outreach. CDC directed a marketing campaign to reach Black/African American and…